Zoetis Inc. — Q3 2023 Form 10-Q
Business context and reporting period. Zoetis is a global animal-health company selling medicines, vaccines, diagnostics and related products across companion-animal and livestock markets. This unaudited report covers the quarter and nine months ended September 30, 2023; international subsidiaries’ results are generally reported through August 31.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $2.151B | $2.002B | $6.331B | $6.040B |
| Net income attributable to Zoetis | $596M | $529M | $1.819B | $1.653B |
| Diluted GAAP EPS | $1.29 | $1.13 | $3.93 | $3.51 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $1.456B | $1.171B |
- Q3 revenue rose 7% reported and 8% operationally; nine-month revenue rose 5% reported and 7% operationally. Foreign exchange reduced growth by approximately 1 and 2 percentage points, respectively.
- Gross margin, calculated from revenue less cost of sales, was approximately 70.3% for Q3 and 71.0% for the nine-month period, versus 69.7% and 70.2% in 2022. Reported International segment gross margin declined to 68.0% from 71.2% in Q3 and to 68.9% from 70.9% year to date; U.S. segment margin also declined modestly.
- Adjusted net income, a non-GAAP measure, was $629M in Q3 (+11%) and $1.888B for nine months (+7%). Adjusted diluted EPS was $1.36 (+12%) and $4.08 (+9%), respectively.
- At September 30, cash and cash equivalents were $1.754B, total debt net of discounts and issuance costs was $6.552B, working capital was $4.614B, and the current ratio was 3.87:1. The $1.0B revolving credit facility was undrawn; the company reported covenant compliance.
- Nine-month capital expenditures were $534M. Cash dividends paid were $520M, and share repurchases were $857M. The company declared dividends of $0.75 per share year to date.
Changes versus comparable prior period
- Q3 net income increased 13%; nine-month net income increased 10%. Growth reflected higher revenue, while reported nine-month results also included unusual income items.
- Companion-animal revenue grew 11% in Q3 and 6% year to date. Growth drivers included key dermatology products, parasiticides, and monoclonal-antibody products for osteoarthritis pain. Livestock revenue grew 1% in Q3 and 3% year to date.
- Cost of sales as a share of revenue improved, with price increases and lower freight costs helping offset manufacturing costs, inventory charges and unfavorable mix. R&D expense increased 13% in both comparison periods.
- Interest expense rose 11% in Q3 and 13% year to date, largely reflecting the higher coupon on replacement notes. The $1.35B of 3.25% notes due 2023 was repaid at maturity in February; replacement notes carry 5.40% due 2025 and 5.60% due 2032.
- Cash fell $1.827B from year-end, mainly due to debt repayment, repurchases and dividends. Operating cash flow increased $285M year over year, partly offset by inventory investment.
Outlook, commentary, risks and unusual items
- Management said cash, operating cash flows and available financing are expected to support cash needs for the next 12 months and beyond, while noting that challenging economic conditions could affect liquidity or access to financing. The filing provides no specific revenue or EPS guidance.
- Q3 revenue growth was driven primarily by approximately 5% price growth, 2% volume growth from new products and 1% from key dermatology products. Nine-month growth had similar price contribution, with approximately 1% each from new products and key dermatology.
- Nine-month results included a $101M pretax gain on sale of a majority interest in Pumpkin pet insurance, including a $24M gain from remeasurement of the retained investment; a royalty settlement for prior-period underpayments; and impairment charges. A $101M gain was recorded in other income, alongside higher foreign-currency losses and impairments.
- Q3 restructuring and acquisition-related costs were $16M; nine-month costs were $45M, primarily employee termination and exit costs and acquisition costs. Q3 included certain diagnostics and precision-animal-health impairments.
- Key exposures include foreign-exchange movements (approximately 43% of nine-month revenue was foreign-currency denominated), disease outbreaks, product safety or quality issues, competition and generic entry, regulation, supply interruptions, distributor stocking variability, inflation, geopolitical and economic uncertainty, and weather or climate impacts.
- Legal proceedings include an environmental matter in Brazil and the Belgium excess-profit tax dispute. Zoetis said it intends to appeal the September 2023 EU General Court ruling confirming illegal state aid; no potential benefit was recognized. Management does not believe the disclosed legal matters will materially affect financial position, but states outcomes are uncertain and excess losses cannot be estimated.
Important facts for investors to verify
- Underlying product demand and the sustainability of reported growth, particularly companion-animal products and international markets; distinguish operational growth from foreign-exchange effects.
- Whether International gross-margin pressure, inventory build-up and manufacturing costs persist or ease.
- The contribution of the pet-insurance divestiture gain and prior-period royalty settlement to reported earnings, and the reconciliation between GAAP and adjusted measures.
- Cash conversion, future capital spending, debt service and continued buybacks/dividends, given the decline in cash and $6.552B of reported long-term debt.
- Developments in the Belgium tax appeal, Brazil environmental matter, uncertain tax positions and disclosed product, regulatory, currency and supply-chain risks.